Therapeutics targeting VISTA curb the development of graft-versus-host disease and promote the death of naive CD4+ T cells; thus, VISTA can be regarded as a distinctive immunotherapy molecule (51, 52). This evidence concerns the gene CD4 and graft versus host disease.